| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $27,488,051 ) (Continued on the next page) |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA225947 | Relationships between parity, breastfeeding and ER- breast cancer in African American women: Elucidating the biologic underpinnings at the molecular and cellular level. | 001 | 4 | NIH | 6/17/2022 | $49,007 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA225947 | Relationships between parity, breastfeeding and ER- breast cancer in African American women: Elucidating the biologic underpinnings at the molecular and cellular level. | 000 | 4 | NIH | 11/4/2021 | $551,329 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | F30CA254327 | The Wnt-IRF8 axis: a Novel Regulator of Myeloid-Derived Suppressor Cell Biology | 000 | 3 | NIH | 7/26/2022 | $51,752 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA240290 | Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells | 000 | 4 | NIH | 6/1/2022 | $423,743 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | F31CA260942 | Impact of benzodiazepines on the pancreatic tumor microenvironment | 002 | 1 | NIH | 8/11/2022 | $716 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | F31CA260942 | Impact of benzodiazepines on the pancreatic tumor microenvironment | 001 | 1 | NIH | 12/13/2021 | $0 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | F31CA260942 | Impact of benzodiazepines on the pancreatic tumor microenvironment | 000 | 1 | NIH | 12/13/2021 | $30,601 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R25CA181003 | Summer Research Experiences in Cancer Science and Oncology | 002 | 9 | NIH | 7/27/2022 | $299,628 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA130995 | Replication Licensing in Genome Stability, Cancer and Aging | 000 | 15 | NIH | 6/10/2022 | $359,878 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA243456 | Radiogenomic Credentialing of Head and Neck Cancer Models | 001 | 2 | NIH | 6/17/2022 | $48,774 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA243456 | Radiogenomic Credentialing of Head and Neck Cancer Models | 000 | 2 | NIH | 11/18/2021 | $548,709 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | P30CA016056 | Roswell Park Cancer Center Support Grant | 005 | 45 | NIH | 6/23/2022 | $75,690 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | P30CA016056 | Roswell Park Cancer Center Support Grant | 003 | 45 | NIH | 6/9/2022 | $4,360,426 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | P30CA016056 | Roswell Park Cancer Center Support Grant | 004 | 45 | NIH | 6/15/2022 | $0 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | P30CA016056 | Roswell Park Cancer Center Support Grant | 006 | 45 | NIH | 7/5/2022 | $115,000 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | U24CA274159 | Coordinating and Data Management Center for Acquired Resistance to Therapy Network | 000 | 1 | NIH | 8/11/2022 | $1,050,404 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R03TR003344 | CRISPR-mediated engineering and pilot study of mouse mutants of the bitter taste receptor genes | 000 | 1 | NIH | 6/17/2022 | $176,711 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R00HL155792 | Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GVT) Responses | 000 | 3 | NIH | 5/7/2022 | $249,000 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | F99CA274655 | Impact of Numeracy on Risk Perceptions of Tobacco-Related Diseases | 000 | 1 | NIH | 7/21/2022 | $33,780 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R21CA267002 | Tumor and immune cell co-evolutionary dynamics as a source of racial disparities in breast cancer | 000 | 1 | NIH | 7/28/2022 | $243,334 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA267647 | Delineating the dystopian nature of the cell cycle in cancer | 000 | 1 | NIH | 6/3/2022 | $549,360 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA273231 | Dissecting the Mechanism of SETDB1 and its K867 Monoubiquitination in Lung Cancer Progression | 000 | 1 | NIH | 7/30/2022 | $401,691 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01ES034250 | STAG2 modulates environmental toxicant exposures and epigenomic heterogeneity | 000 | 1 | NIH | 3/18/2022 | $578,970 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R03CA262845 | Leveraging tissue-specific regulatory maps and network-assisted analysis to identify novel genetic risk loci for esophageal adenocarcinoma | 000 | 1 | NIH | 3/3/2022 | $84,100 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01DK128615 | Genetic susceptibility to Barrett's esophagus: From GWAS to biology | 000 | 1 | NIH | 12/20/2021 | $762,225 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R21CA259719 | A Novel Treatment Strategy for Metastatic Breast Cancer | 000 | 1 | NIH | 12/14/2021 | $235,901 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R21CA267274 | Development of TLR5 agonist based approaches to boost chemo-immunotherapy by modulating immunosuppressive networks | 000 | 1 | NIH | 12/22/2021 | $235,901 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA258337 | Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence | 000 | 1 | NIH | 12/15/2021 | $665,941 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R03CA256122 | Examining the impact of endogenous CD28 signaling on CAR T cells | 000 | 2 | NIH | 11/22/2021 | $84,100 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA246437 | Hsp60 Regulation of Prostate Cancer Progression | 000 | 2 | NIH | 8/11/2022 | $377,062 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01EB029398 | Synchronized brain dynamics and eye movement trajectory for objective evaluation of robot-assisted surgical skills | 001 | 3 | NIH | 6/24/2022 | $359,997 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01EB029398 | Synchronized brain dynamics and eye movement trajectory for objective evaluation of robot-assisted surgical skills | 002 | 3 | NIH | 6/30/2022 | $39,308 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01EB029398 | Synchronized brain dynamics and eye movement trajectory for objective evaluation of robot-assisted surgical skills | 000 | 3 | NIH | 2/8/2022 | $353,767 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA255515 | Metformin for chemoprevention of lung cancer in obese subjects at high risk | 000 | 2 | NIH | 7/25/2022 | $584,429 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA262899 | Multi-ethnic high-throughput study to identify novel non-HLA genetic contributors to mortality after blood and marrow transplantation | 000 | 2 | NIH | 7/25/2022 | $463,641 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R21DA053614 | Assessing the impacts of the four 2019/2020 US federal-level tobacco control actions: flavors, youth marketing, youth access, and Tobacco 21 | 000 | 2 | NIH | 4/13/2022 | $180,439 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R21CA256321 | Development of a Novel Immunotherapy Platform for Triple-Negative Breast Cancer | 000 | 2 | NIH | 6/22/2022 | $192,653 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | K08CA252161 | Therapeutic implication of RB1 loss in bladder cancer | 000 | 2 | NIH | 2/28/2022 | $285,729 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R21CA245448 | Synthetic rocaglates as promising therapeutic agents for aggressive hematological malignancies | 001 | 2 | NIH | 5/11/2022 | $13,723 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R21CA245448 | Synthetic rocaglates as promising therapeutic agents for aggressive hematological malignancies | 000 | 2 | NIH | 1/31/2022 | $154,390 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | K99HL155792 | Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GvT) Responses | 001 | 2 | NIH | 5/6/2022 | $0 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | K99HL155792 | Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GvT) Responses | 000 | 2 | NIH | 2/28/2022 | $117,864 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA251545 | Functional Significance of individual p53 mutations in determining the role of estrogen receptor beta in triple negative breast cancer | 001 | 2 | NIH | 5/9/2022 | $48,926 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | UG3CA260602 | Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting | 000 | 2 | NIH | 5/27/2022 | $1,004,241 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA251545 | Functional Significance of individual p53 mutations in determining the role of estrogen receptor beta in triple negative breast cancer | 000 | 2 | NIH | 2/21/2022 | $550,378 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | U01CA256801 | Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer | 001 | 2 | NIH | 6/1/2022 | $585,015 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | U01CA256801 | Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer | 003 | 2 | NIH | 6/10/2022 | $423,072 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R03CA246001 | Novel 7SK non-coding RNA fusions in soft tissue sarcomas to tumorigenesis | 000 | 2 | NIH | 3/1/2022 | $84,100 |
| | 2022 | 2022 | HEALTH RESEARCH, INC. | ELM AND CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA252092 | Mechanisms of metabolic stress-induced transcriptional regulation in prostate cancer | 000 | 2 | NIH | 3/11/2022 | $325,532 |
|
| Loading… |
|
